Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Phase III study of PhotoPoint therapy in AMD enrolling patients

Jan. 8, 1999

New hope for AMD sufferers: verteporfin proves effective and safe in TAP investigation

Jan. 8, 1999

Ophthalmic INS-365 to be developed by Inspire in collaboration with Santen

Jan. 5, 1999

AF1 promotes optic nerve regeneration in mouse model of glaucoma

Dec. 17, 1998

Medarex reports setback in phase III trial of MDX-RA

Dec. 15, 1998

FDA advisory committee will meet in January to review KeraVision Ring PMA

Dec. 9, 1998

Senju reports synthesis and evaluation of compounds with multiple pharmacological actions

Dec. 8, 1998

Photogen initiates development of ocular disease Rx; receives U.S. patents for technology

Dec. 7, 1998

Olopatadine combination more effective than loratadine monotherapy in allergic conjunctivitis

Nov. 27, 1998

CytoTherapeutics receives patent protection for ocular delivery of therapeutic substances

Nov. 25, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...